<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669458</url>
  </required_header>
  <id_info>
    <org_study_id>CP-001</org_study_id>
    <nct_id>NCT03669458</nct_id>
  </id_info>
  <brief_title>Feasibility Clinical Trial Using the SPUR System to Demonstrate Safety and Efficacy.</brief_title>
  <acronym>DEEPER</acronym>
  <official_title>A Non-RandomizeD FEasibility Trial of the Spur SystEm for the Treatment of Lesions in the InfraPoplitEal ArteRy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ReFlow Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syntropic Corelab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ReFlow Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the Spur System in a patient population with&#xD;
      infrapopliteal artery disease (tibioperoneal, anterior/posterior tibial and peritoneal&#xD;
      arteries) when used in conjunction with substance/drug coated balloons.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to perform a prospective, multi-center (min 2 sites),&#xD;
      non-randomized study to evaluate the safety and efficacy of the Spur system and compare&#xD;
      treatments arms (if applicable) in treating subjects with infrapopliteal disease who are at&#xD;
      risk for amputation.&#xD;
&#xD;
      The study protocol will ensure consistency in performing the procedure, patient management&#xD;
      and results of the procedure. Safety and efficacy will be evaluated during index procedure&#xD;
      through one (1) year follow up&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 6, 2017</start_date>
  <completion_date type="Actual">June 4, 2019</completion_date>
  <primary_completion_date type="Actual">June 4, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A minimum of 10 patients will be enrolled for treatment of BTK disease</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrate binary arterial flow at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>The primary effectiveness endpoint assess arterial flow using duplex ultrasound at 6 months post procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MALE</measure>
    <time_frame>30 days</time_frame>
    <description>The secondary safety endpoint assess Freedom from Major Adverse Limb events (MALE) at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause perioperative death (30 days)</measure>
    <time_frame>30 days</time_frame>
    <description>The secondary safety endpoint assess all-cause perioperative death (POD) at 30 days</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Device and procedure related death through 30 days post procedure.</measure>
    <time_frame>30 days</time_frame>
    <description>The safety endpoint assess freedom from device and procedure-related death through 30 days post-procedure and freedom from target limb major amputation</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically driven target lesion revascularization through 12 months post procedure.</measure>
    <time_frame>12 months</time_frame>
    <description>The safety endpoint assess clinically driven target lesion revascularization through 12 months post procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Freedom from major target amputation through 30 days from the device or procedure</measure>
    <time_frame>30 days</time_frame>
    <description>The safety endpoint from freedom of major target amputation.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>Arm 1: BTK intervention with SPUR/DCB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Below the knee peripheral intervention using SPUR/DCB.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: BTK intervention using SPUR Only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Below the knee peripheral intervention using SPUR only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM 3: BTK intervention using DCB Only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Below the knee peripheral intervention using DCB only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Below the Knee peripheral intervention</intervention_name>
    <description>Treatment of infrapopliteal disease using SPUR/DCB, SPUR only and DCB alone</description>
    <arm_group_label>ARM 3: BTK intervention using DCB Only</arm_group_label>
    <arm_group_label>Arm 1: BTK intervention with SPUR/DCB</arm_group_label>
    <arm_group_label>Arm 2: BTK intervention using SPUR Only</arm_group_label>
    <other_name>DCB Treatment</other_name>
    <other_name>SPUR with DCB treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is willing and able to provide informed consent and able to comply with the&#xD;
             study protocol.&#xD;
&#xD;
          -  Peripheral arterial disease that can be treated using PTA.&#xD;
&#xD;
          -  Life expectancy &gt;1 year in the investigator's opinion&#xD;
&#xD;
          -  Male or non-pregnant female &gt; 18 years of age&#xD;
&#xD;
          -  Patent inflow artery&#xD;
&#xD;
          -  Target vessel(s) reconstitutes(s) at or above the ankle, excluding the dorsalis pedis&#xD;
             and the calcaneal branch of the posterior tibial artery&#xD;
&#xD;
          -  Target lesion starts at or below 3 cm below the tibial plateau as measured by&#xD;
             angiography&#xD;
&#xD;
          -  Target vessel for Spur device is ≥ 3.5 mm (4mm); ≥ 2.5 mm (3mm) in diameter by visual&#xD;
             estimate.&#xD;
&#xD;
          -  Lesion(s) must be able to be treated with a minimum of one Spur or PTA or DCB product.&#xD;
&#xD;
          -  Infrapopliteal lesion(s) that are located in either the left or right leg&#xD;
             Infrapopliteal artery(s) may be treated with only one modality per artery: DCB, Spur&#xD;
             or Spur/DCB.&#xD;
&#xD;
          -  Arterial length/diameter and quantity must be able to be treated with DCB or Spur or&#xD;
             Spur/DCB&#xD;
&#xD;
          -  The treated segment is defined as the total length of artery treated with PTA.&#xD;
&#xD;
          -  The cumulative treated segment of infrapopliteal artery(s) must be ≤34.0 cm.&#xD;
&#xD;
          -  Lesions in the treated segment may be continuous or may have gaps present between&#xD;
             stenosis or occlusions&#xD;
&#xD;
          -  Patient has Rutherford Classification of 3-5.&#xD;
&#xD;
          -  Successful pre-dilatation of the target lesion.&#xD;
&#xD;
          -  Iliac, SFA and popliteal inflow lesions can be treated during the same procedure using&#xD;
             standard angioplasty and/or approved device. These inflow lesions must be treated&#xD;
             first, prior to consideration of treatment of infrapopliteal lesions.&#xD;
&#xD;
          -  The patient can be enrolled if the inflow lesions have acceptable angiographic results&#xD;
             (must have &lt;30% residual stenosis and no evidence of embolization or flow limiting&#xD;
             dissection)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject unwilling or unlikely to comply with the appropriate follow up time for the&#xD;
             duration of the study&#xD;
&#xD;
          -  Prior stent(s) or bypass surgery within the target vessel(s)&#xD;
&#xD;
          -  Target lesion is located within an aneurysm or associated with an aneurysm in the&#xD;
             vessel segment either proximal or distal to the target lesion.&#xD;
&#xD;
          -  Previous treatment failure of inflow arteries (Iliac, SFA and popliteal) which&#xD;
             required a surgical procedure.&#xD;
&#xD;
          -  Previous PTA of the target vessel within 30 day prior to index procedure&#xD;
&#xD;
          -  Angiographic evidence of thrombus within target limb.&#xD;
&#xD;
          -  Subject has an active infection of the foot, including pus or wet gangrene that is not&#xD;
             controlled at the time of the procedure.&#xD;
&#xD;
          -  Planned major (above the ankle) amputation of the target limb&#xD;
&#xD;
          -  Recent MI or stroke &lt; 30 days prior to the index procedure.&#xD;
&#xD;
          -  Heart failure with Ejection Fraction &lt; 30%&#xD;
&#xD;
          -  Impaired renal function (GFR &lt;30 mL/min) and patients on dialysis&#xD;
&#xD;
          -  Subject with vasculitis, systemic Lupus Erythematosus or Polymyalgia Rheumatica.&#xD;
&#xD;
          -  Patient receiving systemic corticosteroid therapy.&#xD;
&#xD;
          -  Inability to tolerate concomitant antiplatelet and oral anticoagulation therapy.&#xD;
&#xD;
          -  Known allergies or sensitivities to heparin, aspirin (ASA), other anticoagulant&#xD;
             therapies which could not be substituted, and/or paclitaxel or an allergy to contrast&#xD;
             media that cannot be adequately pre-treated prior to the index procedure.&#xD;
&#xD;
          -  The patient is currently enrolled in another investigational device or drug trial that&#xD;
             is interfering with the endpoints of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jihad Mustapha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Advanced Cardiac &amp; Vascular Centers</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Nacional de la Diabetes (INDEN)</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All data need to be analyzed</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

